9:00 am
Check-in
10:00 am
Welcome
10:15 am
Session I
Navigating the bridge from lab to clinic in stem cell-based therapies
Keynote
Thomas Hassing Ronøe Carlsen (Novo Nordisk, Denmark)
Optimising efficacy of tumor-specific T cells and manufacturing scalability
Keynote
Felix Lorenz (Captain T Cell, Germany)
Engineering persistence in off-the-shelf cell therapies
Keynote
Karl-Johan Malmberg (University of Oslo, Norway)
11:45 am
Break
12:00 pm
AstraZeneca industry symposium
Supported by AstraZeneca GmbH
The evolving CAR-T landscape in multiple myeloma: Advances in design, targeting, and manufacturing
Prof. Dr. Johannes Waldschmidt, Berlin
Prof. Dr. Michael Hudecek, Würzburg
12:45 pm
Break
1:30 pm
Johnson&Johnson industry symposium
Supported by J&J Innovative Medicine Janssen-Cilag GmbH
2:15 pm
Break
2:30 pm
Session II
Reprogramming the tumor microenviroment toward immune activation by targeted gene-based cytokine delivery
Keynote
Luigi Naldini (Vita-Salute San Raffaele University, Italy)
Fantastic parvoviral gene therapy vectors and how to find them
Keynote
Dirk Grimm (University of Heidelberg, Germany)
Flash Talk
PlasmidFactory
Inducing immunogenic lymphoid niches across cancers by tumor-to-dendritic cell reprogramming
Gaia Fontanari (Sweden)
4:00 pm
Poster session I
5:00 pm
Session III
t.b.a.
Keynote
Angela Vollstedt (Novartis, Austria)
The evolving field of cellular therapy in LBCL
Keynote
Anna Sureda (Catalan Institute of Oncology, Spain)
Longitudinal clonal tracking of ciltacabtagene autoleucel in relapsed / refractory multiple myeloma
Michael Rade (Germany)
Development of novel CAR cell therapeutics in pediatric AML
Sabrina Schuster (Germany)
6:30 pm
Get-together
9:00 am
Session IV
Flash Talk
Understanding the barriers of CAR-T therapy and development towards point-of-care operational models
Dominik Griebling (Fresenius, Germany)
Supported by Fresenius SE & Co. KGaA
Allogeneic TCR-engineered NK cells as an off-the-shelf platform for intracellular antigen targeting in infection and cancer
Frederik Feigl (Germany)
9:45 am
Break
10:00 am
Session IV
Role of microbiome for response to chemotherapy and immunotherapy in gastrointestinal cancers
Keynote
Joseph Tintelnot (Universitätsklinikum Hamburg-Eppendorf, Germany)
t.b.a.
Keynote
Florence Renaud (Sorbonne University, France)
Loss of LEDGF/p75 disrupts DNA damage signaling and sensitizes patient-derived colorectal cancer cells to 5-fluorouracil
Victoria Liedtke (Germany)
Functional MMR empowers efficient cDC1 reprogramming in MSS colorectal cancer
Sandra Schwarz (Germany)
11:30 am
Break
11:45 am
BMS industry symposium
Supported by Bristol Myers Squibb GmbH & Co. KGaA
12:30 pm
Break
1:15 pm
Poster session II
2:15 pm
Session V
In vivo CAR T cells have reached the clinical stage
Keynote
Christian Buchholz (Paul Ehrlich Institut, Germany)
Karolinska ATMP Center & future manufacturing for in vivo CAR T cell therapies
Keynote
Knut Steffensen (Karolinska Institutet, Sweden)
Keynote
Stephan Mielke (Karolinska Institutet, Sweden)
Clinical and manufacturing advances in allogeneic NK and CAR-NK cell therapy: From MRD-positive AML to autoimmune disease
Jan Spanholtz (Glycostem, The Netherlands)
A next-generation ionizable lipid LNP platform for efficient in vivo CAR T cell generation across species through passive and active immune cell targeting strategies
Martin Rabel (Cytiva, Canada)
